Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as the company investigates four reported stroke events.

Shares in the NYSE-listed company dropped 2.8% at market open following the earnings, possibly a reflection of 2025 guidance.

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ('Johnson & Johnson') (NYSE:JNJ) concerning ...

Opens in a new tab or window Just months after FDA approval, Johnson & Johnson paused the rollout of its Varipulse pulsed field ablation (PFA) platform in the U.S. due to safety reasons.

All ablation cases set to use the Varipulse pulsed-field ablation (PFA) system have been temporarily halted in the United States after four neurovascular events were reported during an external ...

Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to treat atrial fibrillation (AFib) in the United States, as it ...

J&J said it temporarily paused the use of the heart device, Varipulse, while it probes the cause of four reported “neurovascular events” in patients. J&J said the pause doesn’t affect ...

Jan 8 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday it had temporarily paused the rollout of its Varipulse heart device in the United States, as the company investigates ...

Johnson & Johnson’s medtech leader said Wednesday that the company is now working with the Food and Drug Administration about safety risks tied to its Varipulse pulsed field ablation device.